Boltwood Capital Management bought a new position in Allergan plc (NYSE:AGN) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 3,915 shares of the company’s stock, valued at approximately $935,000.
A number of other institutional investors also recently modified their holdings of AGN. Sunbelt Securities Inc. acquired a new stake in Allergan plc during the fourth quarter worth approximately $107,000. First Interstate Bank raised its stake in Allergan plc by 1,731.4% in the fourth quarter. First Interstate Bank now owns 641 shares of the company’s stock worth $135,000 after buying an additional 606 shares in the last quarter. Massey Quick & Co. LLC acquired a new stake in Allergan plc during the fourth quarter worth approximately $136,000. Citizens Financial Group Inc RI raised its stake in Allergan plc by 133.9% in the third quarter. Citizens Financial Group Inc RI now owns 601 shares of the company’s stock worth $138,000 after buying an additional 344 shares in the last quarter. Finally, Trust Co. of Vermont raised its stake in Allergan plc by 17.1% in the third quarter. Trust Co. of Vermont now owns 638 shares of the company’s stock worth $147,000 after buying an additional 93 shares in the last quarter. Hedge funds and other institutional investors own 86.40% of the company’s stock.
Shares of Allergan plc (NYSE:AGN) traded down 0.63% during midday trading on Friday, hitting $236.45. The company had a trading volume of 1,243,033 shares. Allergan plc has a 52 week low of $184.50 and a 52 week high of $261.27. The firm’s 50 day moving average is $238.85 and its 200 day moving average is $221.59. The company has a market capitalization of $79.26 billion, a P/E ratio of 6.19 and a beta of 1.07.
Allergan plc (NYSE:AGN) last announced its earnings results on Wednesday, February 8th. The company reported $3.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.76 by $0.14. The company earned $3.86 billion during the quarter, compared to the consensus estimate of $3.77 billion. Allergan plc had a net margin of 100.04% and a return on equity of 7.21%. Allergan plc’s revenue was up 7.1% compared to the same quarter last year. During the same period last year, the firm earned $3.41 earnings per share. Equities research analysts anticipate that Allergan plc will post $16.03 EPS for the current year.
WARNING: This story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/21/boltwood-capital-management-invests-935000-in-allergan-plc-agn-updated.html.
A number of brokerages recently issued reports on AGN. Citigroup Inc reissued a “focus list” rating and issued a $261.27 target price (up previously from $184.50) on shares of Allergan plc in a research report on Friday. Sanford C. Bernstein set a $275.00 target price on Allergan plc and gave the company a “buy” rating in a research report on Sunday, December 25th. Royal Bank of Canada set a $279.00 target price on Allergan plc and gave the company a “buy” rating in a research report on Wednesday, April 12th. Mizuho reaffirmed a “buy” rating and set a $273.00 price target on shares of Allergan plc in a research report on Friday, January 6th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and set a $274.00 price target on shares of Allergan plc in a research report on Tuesday, February 14th. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Allergan plc currently has a consensus rating of “Buy” and an average target price of $266.16.
In other Allergan plc news, Director Paul Bisaro sold 70,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $246.68, for a total value of $17,267,600.00. Following the completion of the sale, the director now directly owns 274,226 shares in the company, valued at $67,646,069.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.27% of the stock is owned by company insiders.
About Allergan plc
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.